Michael Tesar

This inventor holds 15 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 6 EPO patents. Top assignees: Morphosys Ag, Pfizer Corporation, Gpc Biotech Ag. Active years: 2009-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael Tesar. Retrieved from https://idiyas.com/inventor/michael-tesar

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 6)

% Patents Active = 73.3

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 2.8

ph-index = 7

Forward Citations = 270(Granted Patents)

Location History:

Weilheim, DE (2009 - 2015)
Weilheim i. Ob., DE (2015)
Augsberg, DE (2012 - 2020)
Friedberg, DE (2017 - 2021)
Freidberg, DE (2024)

Company Filing History:

Universitaetsklinikum Tuebingen

patents

where one patent can have more than one assignee

Years Active: 2009-2024

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11939395 - Generation and profiling of fully human HuCAL gold-derived therapeutic antibodies specific for human CD38 (2024-03-26),

2. 11059902 - Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 (2021-07-13),

3. 10640568 - 4-1BB binding molecules (2020-05-05),

4. 10184005 - Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 (2019-01-22),

5. 9873733 - Anti-staphylococcal antibodies (2018-01-23),

6. 9758590 - Anti-CD38 human antibodies and uses thereof (2017-09-12),

7. 9468678 - Method of producing 4-1BB binding molecules and associated nucleic acids (2016-10-18),

8. 9200061 - Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i (2015-12-01),

9. 9193799 - Fully human therapeutic antibodies specific for human CD38 (2015-11-24),

10. 8821867 - 4-1BB binding molecules (2014-09-02),

11. 8486394 - Generation and Profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 (2013-07-16),

12. 8337850 - 4-1BB binding molecules (2012-12-25),

13. 8263746 - Anti-CD38 human antibodies and uses thereof (2012-09-11),

14. 8088896 - Generation and profiling of fully human gold-derived therapeutic antibodies specific for human CD38 (2012-01-03),

15. 7521047 - Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells (2009-04-21),

Title: The Innovative Journey of Michael Tesar

Introduction: Michael Tesar, a pioneering inventor hailing from Friedberg, Germany, has made significant contributions to the world of technology and innovation through his groundbreaking inventions.

Latest Patents: Michael Tesar's latest patents include a cutting-edge virtual reality device that revolutionizes the gaming industry, a sustainable energy solution that aims to combat climate change, and a medical device designed to improve patient outcomes in the healthcare sector.

Career Highlights: With a career spanning over two decades, Michael Tesar has established himself as a visionary inventor with a keen eye for identifying gaps in the market and developing innovative solutions to address them. His passion for pushing the boundaries of technology has led to the successful commercialization of several of his inventions, earning him recognition in the industry.

Collaborations: Throughout his career, Michael Tesar has collaborated with leading technology companies, research institutions, and universities to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of many of his projects.

Conclusion: Michael Tesar's relentless pursuit of innovation and his commitment to creating solutions that have a positive impact on society make him a true trailblazer in the field of technology. His contributions continue to inspire the next generation of inventors and shape the future of innovation.

Profile summary based on public USPTO records.